Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fausto Meriggi has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Time Migration in Hepatocellular Carcinoma: Rethinking the Timing of Systemic Therapy Across the Disease Continuum

    by Fausto Meriggi, Ester Oneda, Sara Cherri, Alberto Zaniboni

    The management of hepatocellular carcinoma has traditionally followed a stage-dependent sequence in which surgery or thermal ablation is prioritized for early disease, transarterial approaches are used for intermediate-stage tumors, and systemic treatment is introduced after progression to advanced disease or loss of suitability for locoregional therapy. This paradigm was developed when systemic treatments had limited antitumor activity. Modern immune checkpoint inhibitors and immune–antiangiogenic combinations have substantially changed these premises. Randomized trials now demonstrate clinical benefit when systemic treatment is integrated with transarterial chemoembolization before conventional locoregional failure, while perioperative studies suggest that systemic treatment can also be moved into selected high-risk resectable disease. Conversely, updated adjuvant data indicate that simply administering systemic therapy at an earlier stage does not necessarily improve outcome after complete tumor eradication. We propose the concept of therapeutic time migration, whereby systemic treatment is introduced at an earlier biological point in selected patients, while hepatic reserve is preserved, occult systemic risk is becoming clinically relevant, and effective local treatment remains feasible. We explicitly distinguish this framework from the established concept of treatment stage migration and therapeutic hierarchy. This framework emphasizes treatment sequence rather than treatment escalation and suggests that timing itself may function as a dynamic therapeutic biomarker. Prospective studies should determine whether changing the order of systemic and locoregional therapy can modify immune activation, preserve liver function, increase conversion to definitive local treatment, and ultimately improve survival.

  • Open Access

    Cancer-Related Cognitive Impairment in Breast Cancer: Current State of Knowledge, Mechanisms, Diagnosis, Prevention and Treatment

    by Federica Andreis, Chiara Deori, Valentina Giubileo, Chiara Abeni, Irene Caramella, Sara Cherri, Brunella Di Biasi, Michela Libertini, Silvia Noventa, Chiara Ogliosi, et al.

    Cancer-related cognitive impairment (CRCI), also known as chemobrain or chemofog, is characterized by subjective and/or objective changes in attention, executive functions, memory, and processing speed in patients with non-CNS cancers, particularly women with breast cancer. This structured narrative review synthesizes current evidence on mechanisms, neuropsychological assessment, neuroimaging correlates, clinical and demographic risk factors, emerging artificial intelligence and machine learning applications, and non-pharmacological approaches to CRCI in breast cancer. A structured literature search was conducted using PubMed/MEDLINE, PsycInfo, and Clinical Key up to May 2026, with emphasis on studies published between 2023 and 2026. Peer-reviewed English-language studies involving adult breast cancer populations and addressing predefined thematic domains of CRCI were considered. Given the heterogeneity of study designs, assessment tools, interventions, and outcomes, the findings were synthesized narratively. Current evidence supports a multifactorial model of CRCI involving neurobiological, treatment-related, psychological, and behavioral mechanisms. Neuroinflammation, endocrine disruption, oxidative stress, glial alterations, and structural or functional brain changes may contribute to cognitive symptoms; however, the strength of evidence varies, and many findings remain correlational or preclinical. Non-pharmacological interventions, including cognitive training, physical activity, mindfulness-based and psychological approaches, and multimodal digital programs, appear promising as supportive strategies. However, evidence remains heterogeneous, with benefits more consistently reported for patient-reported outcomes, fatigue, emotional distress, and quality of life than for objective neuropsychological performance. CRCI in breast cancer should be approached as a heterogeneous condition requiring early recognition, standardized assessment, and multidisciplinary supportive care. Future research should prioritize longitudinal designs, harmonized endpoints, and a clearer distinction between subjective and objective outcomes.

  • The Impact of Immune-checkpoint Inhibition on the Gastrointestinal Tract in Non-small Cell Lung Cancer

    by Fausto Meriggi, Sara Cherri, Diego Gavezzoli, Tony Sabatini, Claudio Bna, Alberto Zaniboni

    : Immune-checkpoint inhibitor (ICI)-based immunotherapy has become one of the most effective and widely adopted therapeutic approaches in the field of onco-hematology. Among the various malignancies treated with immunotherapy, lung cancer stands out for the frequency and success of its use, ranging from the adjuvant, neoadjuvant, and perioperative settings to advanced metastatic disease. Despite its clinical success, the mechanisms underlying the full spectrum of immune-related adverse events (irAEs) remain poorly understood, with gastrointestinal (GI) toxicity among the most commonly observed complications. Timely recognition and management of these adverse events are therefore essential to prevent progression to severe, potentially irreversible clinical conditions. Corticosteroids continue to represent the mainstay of treatment for irAEs; however, emerging therapeutic agents are showing promise in improving outcomes and minimizing long-term toxicity. In this review, we will explore the primary GI immune-related toxicities associated with ICIs, discuss current management strategies, and examine their relationship with the use of immunotherapy in patients with non-small cell lung cancer (NSCLC).

  • Open Access

    Ocular Toxicities of Anticancer Therapies in the Era of Precision Oncology: A Practical, Clinically Oriented Narrative Review

    by Fausto Meriggi, Ester Oneda, Sara Cherri, Fausto Petrelli, Alberto Zaniboni

    The introduction of modern anticancer therapies, including targeted therapies (TTs), immune checkpoint inhibitors (ICIs), and antibody–drug conjugates (ADCs), has significantly improved survival across a wide range of malignancies. At the same time, these agents have expanded the spectrum of treatment-related adverse events, with ocular toxicities emerging as a clinically relevant and increasingly recognized complication. Ocular adverse events may affect multiple anatomical structures, including the ocular surface, cornea, anterior and posterior segments, and optic nerve, often reflecting drug class-specific biological mechanisms. The pathogenesis of ocular toxicity is multifactorial and includes on-target inhibition of signaling pathways expressed in ocular tissues, off-target effects on rapidly renewing epithelia, non-specific uptake of cytotoxic payloads in ADCs, immune-mediated inflammation associated with ICIs, and microvascular dysregulation observed with selected targeted agents, such as mitogen-activated protein kinase (MEK) inhibitors. Because ocular adverse events are inconsistently reported in clinical trials and frequently described through case reports or pharmacovigilance data, their true incidence is likely underestimated and management strategies remain heterogeneous. This narrative review provides an overview of the epidemiology, biological mechanisms, and clinical manifestations of ocular toxicities associated with contemporary anticancer therapies. In addition, it offers practical, mechanism-based recommendations for prevention, monitoring, and stepwise management, emphasizing the importance of multidisciplinary collaboration to preserve visual function while maintaining effective oncologic treatment.


  • Open Access

    Peritoneal carcinomatosis in metastatic Non-Small Cell Lung Cancer: review of the literature

    by Fausto Meriggi, Sara Cherri, Diego Gavezzoli, Tony Sabatini, Claudio Bna′, Alberto Zaniboni

    Lung cancer has a remarkably high global incidence and ranks among the most frequent malignancies, with mortality rates placing it first worldwide. Although lung cancer typically metastasizes to the brain, bone, adrenal glands, and liver, the advent and efficacy of novel treatments such as immunotherapy and tyrosine kinase inhibitors have been associated with an increasing incidence of metastases in atypical sites, including peritoneal involvement in Non-Small Cell Lung Cancer. Adenocarcinoma is the histological subtype most frequently responsible for peritoneal carcinomatosis. Little is known about the underlying pathogenic mechanisms leading to peritoneal implantation, and diagnosis is often delayed until advanced disease stages, as symptoms are frequently nonspecific and may be mistaken for the natural progression of advanced lung cancer under systemic oncological treatment. Diagnosis is primarily clinical when ascites develops, but imaging modalities such as computed tomography and fluorodeoxyglucose positron emission tomography/computed tomography can be highly informative. Cytological and molecular analysis of peritoneal fluid obtained via drainage also contributes to diagnosis. Treatment mainly relies on systemic therapy for lung cancer with peritoneal metastases, while loco-regional interventions are generally reserved for symptom control. Considerable progress is still needed in the prevention, early diagnosis, and optimal management of peritoneal carcinomatosis, and future research, despite the rarity of cases, should focus on these aspects. In this review, we aim to analyze the limited literature currently available and explore future directions in the approach to peritoneal carcinomatosis in Non-Small Cell Lung Cancer.

  • Open Access

    Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial

    by Chiara Mattioli, Emanuela Olmetto, Marco Banini, Pietro Garlatti, Saverio Caini, Marco Del Riccio, Giovanna Finocchiaro, Paolo Borghetti, Sara Pilotto, Giulio Metro, et al.


  • Open Access

    Decoding Microbiota in Genitourinary Oncology: Biological Mechanisms and Clinical Implications—A Narrative Review

    by Irene Caramella, Chiara Abeni, Sara Cherri, Chiara Ogliosi, Tonino Morena, Giacomo Galvagni, Fausto Meriggi, Alberto Zaniboni

    Genitourinary malignancies are characterized by marked heterogeneity in tumor biology, clinical behavior and therapeutic outcomes. Despite significant progress in surgical and systemic treatments, resistance to therapy remains a major challenge, highlighting the need to identify additional host-related determinants of disease progression and treatment response. Within this framework, converging experimental and clinical evidence indicates that host-associated microbial ecosystems may influence key biological processes involved in tumor–host interactions, including immune modulation, metabolic regulation and inflammatory pathways. Altered microbial profiles have been associated with oncogenic signaling, changes in the tumor microenvironment and differences in clinical benefit from systemic therapies, particularly immunotherapeutic approaches. This review brings together preclinical, translational and clinical evidence on the involvement of microbiota in renal, prostate, bladder and testicular cancers, with attention to biological mechanisms and clinically meaningful correlations with disease characteristics. While current data are largely observational, early interventional studies suggest that modulation of microbial ecosystems may influence therapeutic activity in selected clinical settings. Collectively, these findings support microbiota as a relevant component of genitourinary cancer biology with potential implications for precision medicine approaches.


  • Open Access

    Depression as a Prodromal Symptom of Pancreatic Cancer: A Narrative Review

    by Chiara Deori, Federica Andreis, Valentina Giubileo, Silvia Noventa, Ester Oneda, Fausto Meriggi, Alberto Zaniboni

    Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, typically diagnosed at an advanced stage. The identification of prodromal symptoms could support earlier detection. Among these, depression is frequently reported, raising the question of whether it may represent not only a reactive response but also a paraneoplastic manifestation. Methods: We conducted a narrative review of clinical, epidemiological and biological literature published between 1988 and 2025. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science using predefined keywords related to pancreatic cancer, depression, prodromal symptoms, cytokines, and the kynurenine pathway. Eligible studies included clinical cohorts, population-based analyses, biological investigations, and case reports exploring the temporal or mechanistic link between depression and PDAC. Results: A substantial proportion of patients (10–20%) exhibit depressive symptoms in the months preceding the clinical diagnosis of pancreatic cancer. In several cases, depression occurs independent of weight loss and new-onset diabetes. Biological evidence highlights the involvement of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), NF-κB signaling, and activation of the tryptophan–kynurenine pathway (IDO), suggesting a link between tumor-related processes and mood alterations. These mechanistic findings are actually hypothesis-generating, deriving mainly from small clinical cohorts and preclinical models. Clinically, depression is associated with reduced adherence to treatment, poorer quality of life, and shorter survival. However, no specific depressive phenotype has been identified. Conclusions: Depression may represent a potential prodromal symptom of pancreatic cancer, reflecting systemic biological processes as well as psychological reactions. Its utility as a standalone marker remains limited; future studies should integrate psychiatric, clinical and biological biomarker assessments to enhance early clinical diagnosis.


  • Open Access

    What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT

    by Sara Cherri, Michela Libertini, Silvia Noventa, Ester Oneda, Fausto Meriggi, Alberto Zaniboni

    The treatment landscape of metastatic colorectal cancer (mCRC) has undergone significant evolution, with the introduction of targeted therapies and immunotherapy dramatically altering the management of microsatellite instability-high (MSI-H) tumors. However, the majority of patients, particularly those with microsatellite-stable (MSS) disease, remain refractory to immunotherapy, necessitating the exploration of alternative therapeutic strategies. This review summarizes the current treatment options for heavily pretreated mCRC patients who are not eligible for targeted therapies or clinical trials. Approved therapies for refractory mCRC, including regorafenib, trifluridine/tipiracil (FTD/TPI), and fruquintinib, demonstrate modest survival benefits but are often associated with significant toxicities. Additionally, innovative approaches targeting specific mutations such as KRAS G12C, HER2 amplification, and BRAF V600E are discussed, highlighting emerging combination regimens with immune checkpoint inhibitors and other agents to overcome resistance mechanisms. The potential of rechallenge strategies using previously administered therapies, such as oxaliplatin and anti-EGFR agents, is examined, supported by retrospective and prospective studies. Furthermore, the role of older drugs like mitomycin C in combination with capecitabine is revisited, offering insights into their viability in advanced treatment settings. Ongoing clinical trials with novel agents and combinations are expected to provide further clarity on optimizing sequential treatment regimens and personalizing therapy for mCRC patients. This review emphasizes the need for comprehensive molecular profiling and shared decision-making to improve outcomes and quality of life in this challenging patient population.


  • Open Access

    Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel

    by Fausto Meriggi

    Small-cell lung cancer (SCLC) is a subtype of lung tumor characterized by rapid growth and early metastatic dissemination. It represents approximately 15% of all diagnosed lung cancers, with an annual incidence of over 200,000 cases worldwide. At the time of initial diagnosis, approximately 75–80% of patients already have extrathoracic spread. Almost all patients with SCLC also relapse after achieving a complete response with first-line treatment. Outcomes achievable in second-line treatment are related to the length of time between completion of first-line therapy and disease progression. While first-line chemo-immunotherapy remains the standard of care for initial management, the role of second-line treatment strategies in SCLC has been a topic of significant research and discussion. Second-line treatment options are limited and the results are still disappointing. Several molecules are currently being studied in lines following the first, using immunological targets and cell cycle checkpoints. Among these, particular interest has been placed on anti-PD-1 (programmed cell death-1 protein) and anti-PD-L1 (programmed cell death-ligand 1) monoclonal antibodies, and DLL3 (Delta-like ligand 3), which are being evaluated alone or in combination. Tarlatamab is a novel promising therapeutic antibody currently under investigation for its potential use in previously treated SCLC patients. This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions.